A standardized frankincense extract was safe, well tolerated, and potentially efficacious as an oral treatment in patients with relapsing-remitting multiple sclerosis (RRMS), according to results of a small, nonrandomized study.
Patients receiving the herbal treatment had significantly fewer contrast-enhancing lesions on MRI versus baseline in the study, which was published in the.
“Despite our encouraging results, it is difficult to forecast the efficacy of a standardized frankincense extract in RRMS,” Dr. Stürner and her colleagues wrote in their report on the study.
Boswellic acids, believed to be the active compound in frankincense, has been used as an anti-inflammatory substance for thousands of years in Eastern medicine, according to the study authors.
Frankincense extracts were safe and well tolerated in several small, randomized trials including patients with inflammatory or autoimmune diseases, they noted.
Dr. Stürner and her colleagues tested a standardized frankincense extract in the, an investigator-initiated, open-label, pilot study including 38 patients with RRMS.